Unusual 11 Mid-Day Movers 9/8: (GTXI) (TLRD) (RPRX) Higher; (GEVO) (TSCO) (PIR) Lower

September 8, 2016 12:52 PM EDT
Get Alerts GTXI Hot Sheet
Trade GTXI Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

GTx, Inc. (Nasdaq: GTXI) 53.9% HIGHER; announced the achievement of the Stage 1 milestone for the 9 mg cohort of its Phase 2 clinical trial of enobosarm (GTx-024) to treat women with advanced, estrogen receptor positive (ER+), androgen receptor positive (AR+) breast cancer.

Gevo, Inc. (Nasdaq: GEVO) 26.6% LOWER; announced that it has agreed to sell 24,800,000 Series E units, with each Series E unit consisting of one share of common stock and a half of one Series I warrant to purchase one share of common stock at a public offering price of $0.55 per Series E unit. Gevo has also agreed to sell 3,700,000 Series F units, with each Series F unit consisting of a pre-funded Series J warrant to purchase one share of common stock and a half of one Series I warrant to purchase one share of common stock at a public offering price of $0.54 per Series F unit.

Tailored Brands (NYSE: TLRD) 21.2% HIGHER; reported Q2 EPS of $0.99, $0.06 better than the analyst estimate of $0.93. Revenue for the quarter came in at $909 million versus the consensus estimate of $886.44 million.

Tractor Supply Company (Nasdaq: TSCO) 16.5% LOWER; updated Q3 guidance. Net sales for the third quarter are expected to increase approximately 4.2% to 5.0% to $1.54 billion to $1.55 billion from $1.48 billion in the third quarter of 2015, with comparable store sales ranging from flat to a decrease of (1.0)% versus an increase of 2.9% in last year's third quarter. (The Street was looking for Q3 sales of $1.6 billion.)

Repros Therapeutics Inc. (Nasdaq: RPRX) 15.3% HIGHER; provided the results of the first course of treatment from Repros’ ongoing study of Proellex® for the treatment of premenopausal women with confirmed symptomatic endometriosis.

Clovis Oncology (Nasdaq: CLVS) 14.4% HIGHER; disclosed in an SEC filing on Thursday: The Food and Drug Administration (“FDA”) has notified Clovis Oncology, Inc. (the “Company”) that FDA is not currently planning to hold an advisory committee meeting to discuss the Company’s New Drug Application for rucaparib. As previously announced by the Company, FDA has accepted the Company’s NDA for accelerated approval of rucaparib and granted priority review status to the application with a Prescription Drug User Fee Act (PDUFA) date of February 23, 2017.

Pier 1 Imports, Inc. (NYSE: PIR) 12.8% LOWER; announced preliminary sales and earnings per share data for the second quarter ended August 27, 2016. Second quarter loss per share is expected to be in the range of ($0.06) to ($0.05), excluding one-time items, if any, related to the planned departure of the Company’s Chief Executive Officer, which was announced separately today. (The Street sees Q2 revenue of $424.4 million and loss of $0.03 per share.)

La Jolla Pharmaceutical Company (Nasdaq: LJPC) 12.1% HIGHER; reported positive results from its Phase 1 study of LJPC-401 in patients at risk of iron overload. The Phase 1 study is a multi-center, open-label, dose-escalation study evaluating the safety, tolerability, and effect on serum iron of a single dose of LJPC-401 in patients at risk of iron overload due to conditions such as hereditary hemochromatosis (HH), thalassemia, and sickle cell disease (SCD). Fifteen patients were dosed at escalating dose levels ranging from 1 mg to 20 mg.

Veracyte, Inc. (Nasdaq: VCYT) 11.5% HIGHER; announced that Noridian Healthcare Solutions, the nation's largest Medicare Administrative Contractor (MAC), has issued a draft local coverage determination (LCD) for the Percepta Bronchial Genomic Classifier. When finalized, this LCD will enable coverage for over 30 million – or more than half – of the Medicare beneficiaries in the United States.

Netlist, Inc. (Nasdaq: NLST) 9.9% LOWER; announced a proposed $15 million underwritten public offering of its common stock, subject to market and other conditions. In addition, the Company intends to grant the underwriters an option to purchase additional shares equal to up to 15% of the aggregate number of shares to be sold in the offering.

Capricor Therapeutics, Inc. (Nasdaq: CAPR) 9.3% LOWER; announced that the randomized Phase I/II HOPE-Duchenne clinical trial has completed its enrollment with 25 subjects. HOPE (Halt cardiomyOPathy progrEssion in Duchenne) is evaluating CAP-1002, Capricor's lead investigational cardiac cell therapy, in Duchenne muscular dystrophy (DMD)-associated cardiomyopathy. Capricor expects to report top-line six-month data from this trial in the first quarter of 2017.

To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

Unusual 11 Mid-Day Movers, Earnings, PDUFA

Add Your Comment